Patient Stories
Preclinical Human Studies
Sophie Ryan
When our cofounder Tracy Ryan’s daughter Sophie was diagnosed with a low-grade brain tumor at 8½ months old, she and her husband, Josh, were devastated. Few advancements had been made in over 40-years for pediatric brain cancers, and the only option for Sophie was toxic chemos that had no chance of curing her disease. It became their mission to find a cure for Sophie, and other patients like her, that didn't have the same toxic outcomes of conventional therapies.
During this journey, Tracy was introduced to Dr. Jewett and learned of her focus on immune function. Dr. Jewett agreed to study Sophie’s immune system to better understand the underlying cause of the disease and assist the clinicians in developing a more effective treatment plan......
Jamie Grooms
Jamie Grooms is a 64-Year-Old male who was diagnosed with CLL (Chronic Lymphocytic Leukemia) in 2021. Jamie was a patient at Mayo Clinic, FL and the conversation around remission stopped when a mutation was found that took his outcome from good to poor. Despite 3-years of targeted therapy, Jamie never achieved remission, with tumor cell infiltration in the bone marrow measuring 20% prior to treatment with NK101. In addition to an elevated B-cell count, the patient suffered with daily body pain, exhaustion, fogginess, and overall discomfort. Patient 1 received a single infusion of approximately 350 million NK101 cells on December 5, 2023, with post-infusion blood work showing a positive early immune response and no adverse safety events. The 90-day review of the post-infusion test results provide early signs of partial remission after only one treatment, with validated data points confirming NK101’s ability to target and spontaneously kill the tumor cells that had infiltrated the bone marrow; reverse disease progression; and restore partial immune function. The early clinical data is consistent with Dr. Jewett's preclinical results.
